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SUMMARY
Botulinum neurotoxin (BoNT) is one of the most acutely lethal toxins known to humans, and 
effective treatment for BoNT intoxication is urgently needed. Single-domain antibodies (VHH) 
have been examined as a countermeasure for BoNT because of their high stability and ease of 
production. Here, we investigate the structures and the neutralization mechanisms for six unique 
VHHs targeting BoNT/A1 or BoNT/B1. These studies reveal diverse neutralizing mechanisms by 
which VHHs prevent host receptor binding or block transmembrane delivery of the BoNT protease 
domain. Guided by this knowledge, we design heterodimeric VHHs by connecting two 
neutralizing VHHs via a flexible spacer so they can bind simultaneously to the toxin. These 
bifunctional VHHs display much greater potency in a mouse co-intoxication model than similar 
heterodimers unable to bind simultaneously. Taken together, our studies offer insight into antibody 
neutralization of BoNTs and advance our ability to design multivalent anti-pathogen VHHs with 
improved therapeutic properties.
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Graphical Abstract
In Brief
Botulinum neurotoxins (BoNTs) are extremely toxic biothreats. Lam et al. report the crystal 
structures and neutralizing mechanisms of six unique antitoxin VHHs against BoNT/A1 and 
BoNT/B1, the two major human pathogenic BoNTs. They then develop a platform for structure-
based rational design of bifunctional VHH heterodimers with superior antitoxin potencies.
INTRODUCTION
Botulinum neurotoxins (BoNTs) are the most potent toxins to humans. BoNT exposure 
inhibits the release of acetylcholine in presynaptic neurons, leading to a flaccid 
neuromuscular paralysis that causes death by respiratory collapse. There are seven classical 
BoNT serotypes (designated A through G), with several new BoNT or BoNT-like serotypes 
identified within the past several years (Tehran and Pirazzini, 2018). BoNT/A, /B, /E, and /F 
are the etiological sources of most cases of endemic human botulism. Although naturally 
occurring botulism is rare, BoNTs can be misused as a bioweapon and, thus, have been 
classified as tier 1 select agents by the Centers of Disease Control and Prevention (CDC). 
BoNT/A and BoNT/B are also increasingly used therapeutically for the treatment of 
numerous medical conditions, thereby creating the accompanying risk of iatrogenic 
botulism.
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Structurally, each BoNT molecule is composed of a light chain (LC; the protease domain) 
and a heavy chain (HC) comprised of an N-terminal translocation domain (HN) and a C-
terminal receptor-binding domain (HC). Functionally, HC determines neuronal specificity by 
recognizing a polysialoganglioside (e.g., GT1b) and a protein receptor, synaptotagmin (Syt) 
I/II (for BoNT/B, /G, and /DC) or glycosylated synaptic vesicle protein 2 (SV2) (for 
BoNT/A, /D, /E, and /F), located on the presynaptic membrane (Chai et al., 2006; Jin et al., 
2006; Montecucco, 1986; Stenmark et al., 2008; Yao et al., 2016). HC of BoNT/B, /G, 
and /DC additionally carries a hydrophobic loop, termed the HC-loop, which interacts with 
host membrane lipids (Stern et al., 2018; Zhang et al., 2017; Figure 1A). Under acidic 
conditions, the HN undergoes a pH-induced structural rearrangement and forms a protein 
channel that delivers the unfolded LC to the cytosol (Fischer et al., 2012; Koriazova and 
Montal, 2003; Lam et al., 2018; Montal, 2009). The translocated LC then cleaves cytosolic 
SNARE proteins, thereby blocking neurotransmitter release and nerve transmission 
(Agarwal et al., 2009; Breidenbach and Brunger, 2004).
Currently, the only available antitoxin remedies are polyclonal antibodies from horse or 
human serum, which have known health risks and are in limited supply (Schussler et al., 
2017). Monoclonal antibodies (mAbs) against BoNT/A have been developed under phase 
I/II clinical trials (Espinoza et al., 2019; Nayak et al., 2014). Small proteins such as heavy-
chain-only camelid antibodies (called VHHs, nanobodies, or single-domain antibodies) and 
de novo designed mini-proteins against the toxins are currently being developed as 
alternatives (Chevalier et al., 2017; Conway et al., 2010; Godakova et al., 2019; Mukherjee 
et al., 2012; Thanongsaksrikul et al., 2010). These small proteins have high stability, can be 
economically produced, display high binding affinity, and have been shown to function 
effectively as antitoxins in animal models (Dong et al., 2010; Herrera et al., 2015; Schmidt 
et al., 2016; Sheoran et al., 2015; Vance et al., 2013; Vrentas et al., 2016). However, the 
therapeutic applications of these antitoxins have been limited by a lack of understanding of 
the molecular mechanisms underlying BoNT neutralization, the extreme potency of BoNTs 
(in vivo lethal blood concentrations at sub-pM), as well as the diverse sequences among 
different BoNT serotypes and subtypes.
In earlier studies, we found that VHH-based neutralizing agents (VNAs) consisting of VHH 
heterodimers joined by a flexible peptide linker possessed significantly improved antitoxin 
potencies (Mukherjee et al., 2012). Similar results have been obtained when developing 
VNAs for other toxins, such as ricin, anthrax, Shiga toxins, and Clostridium difficile toxins 
(Herrera et al., 2015; Schmidt et al., 2016; Sheoran et al., 2015; Vance et al., 2013; Vrentas 
et al., 2016; Yang et al., 2014). We hypothesized that novel heterodimeric VNAs, which are 
composed of two VHHs connected by a spacer that permits simultaneous binding, could be 
rationally designed based on structural and mechanistic knowledge of individual VHHs. 
Such designer VNAs could display greater efficacy due to their substantially improved 
binding kinetics and possibly complementary neutralizing mechanisms.
Here, we carried out comprehensive structure-function characterization on six neutralizing 
VHHs that bind non-competitively, three against BoNT/A1 and three against BoNT/B1. Our 
studies reveal a spectrum of mechanisms by which VHHs attack and neutralize BoNT at 
different stages of intoxication, such as disrupting receptor binding, inhibiting channel 
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formation, and preventing LC delivery. We then demonstrate that designer VNAs composed 
of two VHHs with proximal binding epitopes and distinct neutralizing mechanisms have 
superior potency in a mouse co-intoxication assay over similar VHHs that are unable to bind 
simultaneously. Together, this study establishes a platform for structure-based rational 
design of improved antitoxins against BoNTs.
RESULTS
Isolation of BoNT/B1-Neutralizing VHHs
Our initial goal was to develop bivalent VHHs that neutralize the action of both BoNT/A 
and BoNT/B, which account for 90% of the human botulism cases (Centers for Disease 
Control and Prevention, 2019). We previously reported the characterization of two panels of 
VHHs selected for binding to BoNT/A1 and BoNT/B1 (Mukherjee et al., 2012), including 
several VHHs capable of neutralizing their toxin target. Although we obtained neutralizing 
VHHs recognizing non-overlapping epitopes on all three domains of BoNT/A1, we obtained 
only one neutralizing VHH for BoNT/B1. To seek additional neutralizing BoNT/B-binding 
VHHs, we obtained a new panel of VHHs selected for binding to catalytically inactive 
BoNT/B1 (ciBoNT/B1). The phage-displayed VHHs were derived from several immunized 
alpacas and were selected for binding to plastic-coated ciBoNT/B1 or LC/B or binding to 
ciBoNT/B1 captured by a non-neutralizing VHH (JEQ-H11). The aa sequences of 13 novel 
BoNT/B1-binding VHHs are shown in Figure S1A. We systematically examined their EC50 
binding affinity to ciBoNT/B1, mapped the binding epitopes of these VHHs using ELISA 
against LC/B and HCB, and tested their ability to neutralize BoNT/B1 intoxication using 
primary neurons. All these results are summarized in Table S1 and Figure S1B.
Four Neutralizing VHHs Block BoNT/B1 Binding to Host Receptors
Notably, four of the five most potent neutralizing VHHs (JLK-G12, JLO-G11, JLI-G10, and 
JLI-H11) recognize HCB. In our earlier studies, we identified a potent neutralizing VHH 
(ciA-C2) against BoNT/A1, which binds to the HC domain of BoNT/A1 and prevents its 
binding to its protein receptor SV2 (Yao et al., 2017). But, no neutralizing epitope has been 
mapped to HCB before. To further understand the molecular basis of toxin neutralization by 
these four HCB-binding VHHs, we determined the crystal structures of HCB in complex 
with JLK-G12, JLO-G11, JLI-G10, or JLI-H11 at 2.2 to 3.2 Å resolution (Table S2). 
Structural analysis demonstrated that all four VHHs bind to the C-terminal subdomain 
(HCC) of HCB, which harbors the binding sites for BoNT/B’s protein receptor Syt and 
polysialoganglioside (Figure 1B).
VHH JLI-G10 binding to HCB buries a molecular surface area of ~974 Å2 per molecule 
(calculated by PDBePISA v1.51) (Figure 2A). The structure of the HCB–GD1a (PDB: 
4KBB) complex revealed that the polysaccharide head group of a ganglioside makes 
contacts with a shallow groove in HCB composed of a “E1190 … H1241 … 1260SXWY1263 
… G1277” motif, which is also conserved in other BoNT serotypes (Berntsson et al., 2013; 
Lam et al., 2015; Rummel, 2013). We found that the complementarity-determining region 3 
(CDR3) of JLI-G10 occupies the same area on HCB as GD1a, which should strongly 
compete for ganglioside binding. Specifically, residue R106 of JLI-G10 interacts with 
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E1190, H1241, and W1262 of HCB, and the backbone carbonyl of A104 of JLI-G10 is 
hydrogen bonded with Y1263 and G1277 of HCB. The VHH-HCB complex is further 
strengthened by electrostatic and hydrophobic interactions (Figures S2A and S2D). 
Consistent with the structural finding, JLI-G10 significantly reduced binding of HCB to 
GT1b-containing liposomes in a co-sedimentation assay (Figures 2B and S7D).
Interestingly, JLI-G10 causes a large conformational change in the membrane-binding HC-
loop (E1245–E1252) on HCB by directly binding to the hydrophobic residues I1248 and 
F1250 (Figures 2C and S2D). Prior studies showed that deleting I1248-F1250 in this region 
potently inhibited the binding of HCB to membrane-embedded Syt II, even though these 
residues are not directly involved in binding the luminal domain of Syt II (Dong et al., 2003; 
Stern et al., 2018). It, thus, prompted us to hypothesize that JLI-G10 might also impair the 
association of HCB with the plasma membrane in addition to competing for ganglioside 
binding. To test this hypothesis, we assessed the ability of the HCB–JLI-G10 complex to 
interact with the soluble GST-Syt II luminal domain (residues 1–61) or a membrane-
anchored GST-Syt II (residues 1–90) that carries the transmembrane domain and is solvated 
in Triton X-100 micelles. The latter was shown to faithfully mimic Syt II insertion in a 
membranous environment (Stern et al., 2018). As expected, JLI-G10 did not disturb HCB 
binding to the soluble GST-Syt II (Figures 2D and S7E). However, JLI-G10 completely 
blocked the binding of HCB to GST-Syt II (1–90) embedded in Triton X-100 micelles, even 
in the presence of co-receptor GT1b (Figures 2E and S7F) that should form a cis-complex 
with Syt II in the detergent micelle to enhance HCB binding (Flores et al., 2019). These data 
collectively suggest that JLI-G10 inhibits the binding of BoNT/B1 to neuronal membrane by 
simultaneously occupying the membrane-binding HC-loop and the ganglioside-binding 
pocket on HCB.
The binding sites of JLK-G12 and JLO-G11 on HCB partially overlap with the Syt II-
binding pocket (Jin et al., 2006; Figures 2F, S2, and S3). Because these two VHHs share a 
high sequence identity of ~84% and bind to HCB in a similar manner (root-mean-square 
deviation [RMSD] = 0.41 Å), we focused on JLK-G12 for further study, which has a slightly 
bigger interface with HCB than JLO-G11 (943 Å2 versus 872 Å2). Interestingly, JLK-G12 
shares similarities with Syt II when recognizing HCB. For example, a phenylalanine (F101) 
in the CDR3 loop of JLK-G12 is inserted into the same hydrophobic pocket on HCB that 
otherwise accommodates F54 of Syt II, which is crucial for high affinity binding of BoNT/B 
to Syt II (Figure 2F; Jin et al., 2006). This mimicry suggests that JLK-G12 neutralizes 
BoNT/B1 by blocking its binding to Syt. This is supported by the observation that JLK-G12 
clearly prevented the binding of HCB to GST-Syt II (1–61) (Figures 2D and S7E).
Notably, JLK-G12 partly interacts with the HC-loop of HCB, which suggests that JLK-G12 
may also interfere with lipid binding of HCB (Figures S2B and S2E). Consistent with this 
structural finding, we observed that JLK-G12 inhibited binding of HCB to GT1b-containing 
liposomes in a liposome co-sedimentation experiment, even though it does not directly 
compete with GT1b binding (Figures 2B and S7D). Furthermore, JLK-G12 also inhibited 
binding of HCB to detergent-solvated Syt II (1–90) supplemented with GT1b (Figures 2E 
and S7F). Therefore, JLK-G12 appears to inhibit BoNT/B1 binding to both its neuronal 
protein receptor Syt and plasma membrane, which leads to potent toxin neutralization.
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The neutralizing mechanism of VHH JLI-H11 was initially confusing, because it binds HCB 
in a region that has no known function (Figures 2G, S2C, and S2F). A detailed structural 
analysis revealed that the N terminus of JLI-H11 clashes with the N terminus of a fragment 
of Syt II (residues 44–60) based on the crystal structure of a HCB–Syt II complex. It is worth 
noting that only residues 44 to 60 of Syt II were resolved in this crystal structure, whereas 
Syt II residues N-terminal to this fragment were not observed due to high structural 
flexibility (Jin et al., 2006). Therefore, we hypothesized that JLI-H11 may clash more 
severely with Syt II in a region N-terminal to fragment 44–60. Supporting this notion, we 
found that JLI-H11 partially inhibited HCB binding to both soluble Syt II (1–61) and the 
detergent-solvated Syt II (1–90) (Figures 2D, 2E, S7E, and S7F). As the JLI-H11 epitope 
does not overlap with the HC-loop or the glycolipid-binding pocket of HCB, the HCB–JLI-
H11 complex was able to bind the GT1b-containing liposome and partially interacted with 
detergent-solvated Syt II supplemented with GT1b (Figures 2B, 2E, S7D, and S7F). 
Together, these findings suggest that JLI-H11 neutralizes BoNT/B1 by competing with its 
binding to the protein receptor.
VHH ciA-B5 Blocks Membrane Insertion of BoNT/A1 Translocation Domain
In our earlier work, we obtained a large panel of unique BoNT/A1-binding VHHs 
recognizing seven non-overlapping epitopes on the toxin (Mukherjee et al., 2012). Among 
these VHHs, ciA-B5, ciA-C2, and ciA-H7 potently neutralized BoNT/A1 intoxication 
through binding at unique epitopes. VHH ciA-C2, which binds to the HC domain of 
BoNT/A1, was recently shown to neutralize BoNT/A1 through inhibition of its binding to 
the protein receptor SV2 (Yao et al., 2017). Here, we performed structural analyses on ciA-
B5 and ciA-H7, which bind to HN and LC of BoNT/A1, respectively. We also included 
VHH ciA-D12 as a control for ciA-H7 because ciA-D12 binds to a distinct epitope in LC/A 
and possesses marginal neutralizing activity in cell-based assays (Mukherjee et al., 2012). 
After extensive crystallization screening trials, we successfully crystallized a hetero-
tetrameric complex composed of LCHN/A (residues M1 to K871), including both the LC 
and the HN of BoNT/A1, and all three VHHs in a 1:1:1:1 ratio. The structure of LCHN/A–
B5–D12–H7 was determined at 2.16-Å resolutions (Table S2).
We first focused on the neutralizing mechanism of ciA-B5 that recognizes an epitope on the 
N-terminal boundary of the rod-like HN (Figure 3A). We found that ciA-B5 inhibited the 
HNA-mediated dye release of calcein-loaded asolectin liposomes by over 85% (Figure 3B) 
and potently reduced the ability of HNA to dissipate valinomycin-induced membrane 
potential in anionic liposomes in a concentration-dependent manner (Figure 3C). These data 
demonstrated that ciA-B5 blocks the channel formation of HNA, which is a crucial step 
during BoNT/A intoxication. Interestingly, aa sequence analysis shows that the ciA-B5 
epitope on BoNT/A1 (residues 600–616) partially overlaps with a putative channel-forming 
amphipathic region (Lam et al., 2018; Mansfield et al., 2019) (residues 593–686; Figures 
3A, S2G, S2J, and S4A). Specifically, M39 and Y103 of ciA-B5 interact with L604, V607, 
V611, and Y612 of BoNT/A1, and R60 of ciA-B5 forms a salt bridge with D616 of 
BoNT/A1. Therefore, ciA-B5 may interfere with membrane insertion of its epitope into the 
membrane during channel formation.
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We found that the ciA-B5-bound HNA was still able to interact with anionic liposome and 
showed pH-dependent conformational change (Figures 3D, S4B, and S7L). This is 
consistent with the structure showing that the ciA-B5-binding epitope is distant from the 
“BoNT-switch,” which is a motif crucial for membrane association of HNA at acidic pH 
(Lam et al., 2018; Figure S4A). However, when we pre-incubated HNA with liposomes to 
allow membrane insertion of HNA, co-sedimentation of ciA-B5 with liposome-embedded 
HNA was drastically reduced (Figures 3D and S7M). This finding suggested that ciA-B5 
may inhibit HNA from forming a membrane-embedded channel. Previous studies showed 
that peripherally bound proteins, but not transmembrane or lipid-anchored proteins, could be 
extracted by either 1 M sodium chloride (pH 4.4), 0.1 M sodium bicarbonate (pH 11), or 
phosphate-buffered saline (PBS) (pH 7.4) (Bai et al., 2000; Sun et al., 2011). We found that 
HNA remained bound to liposomes under all these protein extraction conditions, suggesting 
that HNA stably inserts into the liposome. In contrast, about half of the HNA–ciA-B5 
complex was extracted by alkaline solution at pH 11 and by PBS to a less extent, indicating 
that binding of the HNA–ciA-B5 complex to lipids is partially reversible (Figures 3E and 
S7N). Taken together, these findings demonstrate that ciA-B5 is able to block membrane 
insertion of the N-terminal region of HNA and, thus, channel formation of BoNT/A1.
VHHs ciA-H7 and ciA-D12 Interfere with the Unfolding of the Protease Domain
VHHs ciA-H7 and ciA-D12 strongly bind the holotoxin through the surface-exposed regions 
on LC/A (Mukherjee et al., 2012). The strong neutralizing capacity of VHH ciA-H7 was not 
readily explained by its structure because its binding site on LC/A is distant from the 
SNAP-25 binding pocket or the active site of LC/A and has no known function (Figures 4A 
and S4C). Indeed, ciA-H7 and ciA-D12 did not inhibit cleavage of SNAP-25 by LC/A 
(residues 2–438) in vitro (Figure S4D). Therefore, the neutralization activity of ciA-H7 
seems to be unrelated to the protease function of LC/A. We noticed that ciA-H7 directly 
interacts with many secondary structures on LC/A through a very large interface (~1,170 
Å2), covering residues in the long helix α5, three surface loops (Loop120, 170, and 250) and 
α10 of LC/A (Figures 4A, S2I, and S2L). In contrast, the binding interface for ciA-D12 is 
smaller (~778 Å2), mainly including residues in the C-terminal loop, the N-terminal loop, 
and α10 of LC/A. Interestingly, in our earlier study, we found that another VHH (ciA-F12), 
which is not protective against BoNT/A1 in mouse studies, recognizes LC/A through an 
even smaller interface (~684 Å2) involving two surface β-hairpins(Gu et al., 2012; 
Mukherjee et al., 2012; Figures 4A and S4C). These structural findings not only explain the 
higher binding affinity of ciA-H7 in comparison to ciA-D12 and ciA-F12 (Mukherjee et al., 
2012) but also suggest that ciA-H7 may be superior at stabilizing the structure of LC/A. 
Because LC must partially unfold upon endosomal acidification before it can pass through 
the HN channel (~15 Å diameter) to enter the cytoplasm (Koriazova and Montal, 2003), 
agents preventing LC unfolding in endosomes could prevent translocation and, thus, 
neutralize the toxin. Alternatively, ciA-H7 might interfere with LC interactions with the 
membrane and the HN chaperone during translocation and, thus, block trans-membrane 
delivery of LC/A (Montecucco et al., 1988; Pirazzini et al., 2016; Schiavo et al., 1990).
We then asked how these VHHs may affect the thermo-stability and low-pH-induced 
unfolding of LC/A. Using a fluorescence-based thermal shift assay (Figure 4B), we found 
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that the melting temperature (Tm) of LC/A was significantly increased by 30.9%–34.9% at 
pH 4–6.5 in the presence of ciA-H7 and 20.1%–25.4% for ciA-D12, whereas ciA-F12 had 
no effect. We further monitored the effect of these VHHs on low-pH-induced unfolding of 
LC/A by using a hydrophobic dye, ANS. A large increase in fluorescence at pH below 4.8 
was indicative of exposure of hydrophobic surfaces during LC/A unfolding. We found that 
LC/A unfolding was almost completely inhibited by ciA-H7 and by ciA-D12 to a lesser 
extent but not by ciA-F12 (Figure 4C). Together, these data demonstrate that ciA-H7 is able 
to potently prevent LC/A unfolding, which is a prerequisite for membrane translocation of 
LC/A. VHH ciA-D12 has a weaker ability to prevent LC/A unfolding, which may explain 
why ciA-D12 is a comparatively poor LC/A neutralizing agent in cell-based assays 
(Mukherjee et al., 2012).
Structure-Based Design of VHH Heterodimers
In earlier studies, we often observed dramatically increased antitoxin potency when we 
genetically linked two VHHs and produced them as heterodimeric VNAs (Mukherjee et al., 
2012). However, these VNAs were designed empirically without knowing the binding sites, 
neutralizing mechanisms, and their relative positioning of the parental VHHs. Having 
obtained precise structural information on many high-affinity VHHs against BoNT/A1 and 
BoNT/B1, we were now able to rationally design a new generation of heterodimeric VNAs, 
which are composed of two selected VHHs that could bind and/or neutralize toxin 
synergistically. Specifically, the two parental VHHs in each designer VNAs were carefully 
selected so that a flexible spacer could be designed based on the distances between their 
amino or carboxyl termini to allow simultaneous binding to two epitopes on the same toxin 
molecule. When possible, we paired two VHHs with complementary neutralizing 
mechanisms. We used the rigid, inflexible portion of VHHs as building blocks, which begin 
in the framework 1 sequence “QVQLVE…” and end with the framework 4 sequence “…
VSS.” All pairwise distance estimates between VHHs were calculated from these termini. 
The flexible spacers engineered to join two VHHs consisted of either GGGGS repeats or 
poly-glycines, and their spanning lengths can be accurately estimated (Chen et al., 2013).
To test this rational design platform, we designed a series of VNAs containing linkers of 
different lengths that would allow only one VHH to bind at a time or both VHHs to bind 
simultaneously. In one example, the LC/A-binding ciA-D12, a poorly neutralizing VHH, 
was found to bind an epitope on BoNT/A1 holotoxin that is spatially proximal to the epitope 
of ciA-B5, a high-affinity neutralizing VHH binds on HNA. As the estimated distance is ~17 
Å and ~20 Å in the ciA-D12/ciA-B5 and ciA-B5/ciA-D12 orientations, respectively (Figure 
5A; Table S3), we designed an 11-aa peptide linker composed of glycine and serine to 
ensure simultaneous binding of ciA-D12 and ciA-B5 (D12/11/B5). Because the binding sites 
for ciA-D12 and ciA-B5 are close to each other, making it difficult to design a shorter spacer 
to preclude simultaneous binding, we constructed another VNA as a control, in which ciA-
D12 was linked to ciA-H7 that has comparable neutralization potency as ciA-B5 but a 
binding site distant from ciA-D12 (Mukherjee et al., 2012). These two VHHs were linked 
with an 11-aa spacer (D12/11/H7), which is too short to permit simultaneous binding.
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The second set of VNAs were engineered based on VHHs JLI-G10 and JLK-G12, which 
bind at nearby sites on HCB and block BoNT/B1 recognition of its receptors. We engineered 
two VNAs with these two VHHs in opposite orientations: (1) JLI-G10 was linked to JLK-
G12 (distance ~37 Å) with a 12-aa spacer (G10/12/G12) that should permit simultaneous 
binding, and (2) JLK-G12 was linked to JLI-G10 (distance ~80 Å) with a short 5-aa spacer 
(G12/5/G10) to prevent simultaneous binding. A third set of VNA was designed based on 
JLK-G12 and JLI-H11, which is another HCB-binding neutralizing VHH. We designed two 
heterodimers of these two VHHs in the JLI-H11/JLK-G12 orientation (distance ~61 Å) with 
either a 20-aa spacer (H11/20/G12) to permit simultaneous binding or a 3-aa spacer (H11/3/
G12) that is too short for simultaneous binding (Figure 5B; Table S3).
Because these bifunctional VNAs intrinsically have extremely high affinity for their targets, 
it is infeasible to differentiate simultaneous from non-simultaneous binding of parental 
VHHs by SPR-based methods. Therefore, we performed size-exclusion chromatography to 
examine the binding stoichiometry between BoNT domains and VNAs, as VNAs with 
simultaneous binders should form a monomeric complex with BoNT, whereas VNAs with 
non-simultaneous binders should cross-link BoNTs to form high-molecular-weight 
oligomers (Figure 5). We found that D12/11/B5 and LCHN/A formed monomeric complexes 
when these proteins were pre-incubated in 1:1 and 5:1 molar ratios (Figure 5C). 
Simultaneous binding of these two VHHs was further confirmed by the co-crystal structure 
of LCHN/A in complex with the designer VNA (Figures S4E-S4G). In contrast, the non-
simultaneous binding D12/11/H7 cross-linked LCHN/A to form multimeric species with 
higher molecular weight (Figure 5C, bottom panel). A significant amount of VNAs 
G10/12/G12 (Figure 5D) and H11/20/G12 (Figure 5E) formed monomeric complexes with 
HCB, indicating simultaneous binding. But their counterparts G12/5/G10 and H11/3/G12, 
the predicted non-simultaneous binders, only formed oligomeric complexes due to cross-
linking of HCB (Figures 5D and 5E, bottom panels). These data, thus, confirmed that the 
structure-based design of these VNAs was successful.
Simultaneous Binding VNAs Possess Significantly Improved Antitoxin Potency
We next compared the in vivo potency of selected VNAs in a mouse co-intoxication model, 
in which fixed amounts of VNAs were pre-mixed with increasing doses of BoNT/A1 or 
BoNT/B1 and injected into mice, and the mice were monitored for symptoms of intoxication 
and time to death (Figures 6 and 7). We first compared the simultaneous binder D12/11/B5 
with a non-simultaneous binder, D12/11/H7. VNA D12/11/B5 (~40 pmoles) fully protected 
mice from 100 lethal dose 50 (LD50) of BoNT/A1 and delayed death for about 2 days in 
mice receiving 500–1,000 LD50 of toxin, whereas the D12/11/H7-treated mice survived for 
1 day when challenged with 100 LD50 and displayed little protection at high challenge doses 
(Table S3). Only one parental VHH (ciA-B5 or ciA-H7) could neutralize BoNT/A1 in these 
two VNAs. We previously reported a VNA (H7/30/B5), in which two strong neutralizing 
VHHs were connected by a 30-aa peptide linker (Mukherjee et al., 2012). But with the new 
structural information, it is now clear that this peptide linker is too short to allow 
simultaneous binding of ciA-H7 and ciA-B5. Interestingly, we found that the antitoxin 
efficacy of D12/11/B5 was comparable to H7/30/B5. This finding suggests that the 
neutralizing potency of ciA-B5 could be enhanced by a non-neutralizing VHH through 
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synergistic binding in a designer VNA, which could be as potent as a simple addition of two 
neutralizing VHHs.
We then tested designer VNAs composed of two neutralizing VHHs against BoNT/B1 
(Figure 7; Table S3). For designer VNAs H11/20/G12 and G10/12/G12 that allow 
simultaneous binding of parental VHHs, the VNA-treated mice survived a LD50 challenge 
with no or minor signs of botulism, respectively. They partially protected mice when 
exposed to 5,000 LD50 of toxin and significantly delayed death even at 10,000 LD50 of 
toxin. In contrast, the control VNAs H11/3/G12 and G12/5/G10, which contain the same 
parental VHHs as the above two, provided little or no protection in mice challenged with 
1,000 LD50 of BoNT/B1. We speculate that such dramatically improved antitoxin potency 
for H11/20/G12 and G10/12/G12 is caused by both synergistic binding and complementary 
neutralizing mechanisms of the two parental VHHs. Taken together, these results clearly 
demonstrate the advantage of the structure-based VNA design platform.
We further evaluated the practical application of these VNAs as potential antitoxins by 
testing the in vivo potency of selected VNAs when they were administered separately from 
toxins (Figures S5A and S5B). As a proof of concept, VNAs D12/11/B5 or H11/20/G12 
were first administered to mice by tail vein injection, which was followed by giving variable 
doses of BoNT/A1 or BoNT/B1, respectively, by intraperitoneal injection 5 min after VNA 
administration. We found that both D12/11/B5 and H11/20/G12 fully protected mice from 
100 LD50 of the appropriate toxin and delayed death for several days in mice receiving 500–
1,000 LD50 of the toxin. These two VNAs fully protected mice against 10 LD50 of 
BoNT/A1 and BoNT/B1, respectively, when administered 30 or 60 min prior to toxins 
(Figures S5C and S5D).
DISCUSSION
BoNTs can be extremely toxic to animals and humans, and the source bacteria are widely 
distributed in nature and express BoNTs with broad sequence variations. There is a clear 
unmet need for improved treatments for botulism, which should be safe, economical, and 
easily manufactured in large amounts. In this paper, we strive to develop a platform to 
rationally design potent VHH-based antitoxins against BoNTs. Specifically, we first 
investigated the binding epitopes and neutralizing mechanisms for a selected group of 
VHHs. Based on these structural and functional information, we further enhanced the 
potency of these VHHs by rational design of heterodimeric VNAs, which use custom-
designed peptide linkers to achieve simultaneous binding of two parental VHHs that have 
non-overlapping yet closely apposed epitopes (Beirnaert et al., 2017; Desmyter et al., 2017).
We revealed two neutralizing mechanisms against BoNT/A1: (1) ciA-B5 blocks the acidic 
pH-driven insertion of HN into the endosomal membrane, which is required for translocation 
of LC into the cytosol; and (2) ciA-H7 inhibits the pH-dependent conformational change and 
translocation of LC. We also reported the creation of a panel of VHHs that bind to 
BoNT/B1, and we identified three high-affinity, neutralizing VHHs, namely, JLK-G12, JLI-
G10, and JLI-H11, which interfere with receptor binding of BoNT/B1. Interestingly, 
although JLK-G12 and JLI-G10 primarily prevent BoNT/B1 binding to Syt II or 
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ganglioside, respectively, both VHHs also interact with a membrane-binding loop (HC-loop) 
on HCB. The newly discovered HC-loop is located proximately in between the Syt- and the 
ganglioside-binding pockets on HCB, serving as the third membrane anchoring point for 
BoNT/B on neuronal cell surface (Stern et al., 2018). JLK-G12 and JLI-G10 are unique in a 
way that they can block membrane binding of BoNT/B by targeting the HC-loop. A similar 
neutralizing mechanism could be applied to antagonize BoNT/G or /DC, as they share 
similar receptor-recognition mechanisms as BoNT/B (Stern et al., 2018; Zhang et al., 2017). 
On the other hand, BoNT/A, /HA, and other BoNTs that rely on SV2 as their protein 
receptor have spatially distant binding sites for SV2 and ganglioside (Stenmark et al., 2008; 
Yao et al., 2016). It remains unknown whether these BoNTs may also have a membrane-
binding motif equivalent to the HC-loop of BoNT/B that could be targeted by antibodies.
Our designer VNAs display significantly improved antitoxin potencies versus component 
VHHs. In one example, a poorly neutralizing VHH (ciA-D12), when appropriately linked to 
a neutralizing VHH (ciA-B5) that binds at an adjacent site, resulted in a VNA that is as 
potent as a simple addition of two neutralizing VHHs. Combining two neutralizing VHHs in 
a simultaneous binding designer VNA further improved the overall potency, as demonstrated 
by H11/G12 and G10/G12 neutralization of BoNT/B1. Despite the short half-life of 
H11/20/G12 and G10/12/G12 in blood (estimated at 1–2 h), they were as potent as a simple 
combination of two neutralizing mAbs that inhibit BoNT/B dual-receptor binding at non-
overlapping epitopes (Chen et al., 2012). Furthermore, we have shown that the potency of 
VNAs can be further enhanced by including two epitopic tags and co-administering a single 
anti-tag mAb, which promotes rapid serum clearance of the toxin (Mukherjee et al., 2012). 
Therefore, designer VNAs hold great promise as anti-BoNT therapeutic agents.
The designer VNA strategy could also help to tackle another major obstacles in the 
development of botulism antitoxins, which is the high sequence diversity within each BoNT 
serotypes. For example, BoNT/A and /B each have eight distinct subtypes, with additional 
subtypes likely to be discovered. It is well known that primary sequence differences among 
BoNT subtypes can impact antibody binding and neutralization properties (Smith et al., 
2005). We found that the ciA-B5 epitope of BoNT/A is identical among BoNT/A1 and A5–
A8 and is >90% conserved among BoNT/A2–A4 (Figure S6). Hence, ciA-B5 is likely to 
bind well to all BoNT/A subtypes. Sequence analysis showed that the JLI-G10, JLK-G12, 
and JLI-H11 epitopes are moderately conserved among BoNT/B subtypes, suggesting that 
these VHHs likely have some affinity toward most or all BoNT/B subtypes (Figure S6). 
Therefore, a comprehensive structure-based mapping of antibody binding epitopes on 
BoNTs is needed to identify more conserved epitopes on BoNTs, which will aid the 
development of neutralizing antibodies with cross-subtypes or cross-serotype efficacies.
We expect that designer VNAs will have better tolerance to cross-subtype sequence diversity 
because they recognize a much larger surface on BoNTs than individual VHHs (Laursen et 
al., 2018), and the two parental VHHs bind synergistically and could exploit complementary 
neutralizing mechanisms. In addition, the many co-crystal structures of BoNT–VHH 
complexes presented here and in the literature lay the foundation for structure-based 
engineering of VNAs to enhance their neutralizing potencies and broaden reactivity. Taken 
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together, we have established a platform to advance our ability to rapidly and rationally 
develop novel designer VNAs to prevent and/or treat BoNT intoxication.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to the Lead 
Contact, Rongsheng Jin (r.jin@uci.edu). All unique/stable reagents generated in this study 
will be made available on request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Five alpacas, two juveniles (~age 1) and three adults including both males and females, all 
outbred and raised on pasture, were procured from local farm. All studies were carried out in 
strict accordance with the recommendations delineated in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The procedures used were approved 
by the Tufts University Institutional Animal Care and Use Committee (IACUC) and were 
performed under Protocols #G2011-08 and #G2017-18.
CD1 Mice (eight week old, female) were purchased from Charles River Laboratories. All 
procedures were approved by the USAMRICD IACUC and conducted in accordance with 
the principles stated in the Guide for the Care and Use of Laboratory Animals and the 
Animal Welfare Act of 1966 (P.L. 89-544), as amended.
METHOD DETAILS
Cloning, expression, and purification of recombinant proteins—Five alpacas 
were immunized with purified recombinant catalytically inactive BoNT/B1 holotoxin 
(ciBoNT/B1) (Mukherjee et al., 2012) and/or LC/B by five multi-site subcutaneous (SC) 
injections at approximate 3-week intervals essentially as described by Vrentas et al. (2016). 
Blood was obtained for lymphocyte preparation 3–5 days after the fifth immunization, and 
RNA was prepared from lymphocytes using the RNeasy kit (QIAGEN, Valencia, CA). Three 
VHH-display phage libraries were prepared from the lymphocyte RNA from either one 
alpaca or pools of two alpacas, each as described previously by Moayeri et al. (2015). Three 
different libraries were prepared, each having a complexity of > 107 independent clones with 
> 95% containing VHH inserts.
The phage libraries were panned to select and identify VHHs binding to ciBoNT/B1 using 
methods essentially as previously described (Moayeri et al., 2015; Mukherjee et al., 2012). 
Some VHHs were obtained by panning on ciBoNT/B1 that had been immobilized either in 
Nunc Immunotubes or on Costar tissue culture plastic dishes. To select for VHHs binding to 
native ciBoNT/B1, a further round of panning was performed in which phage from one 
library was selected for binding to soluble ciBoNT/B1 that had been captured onto Nunc 
Immunotubes that were first coated with the ciBoNT/B1-binding VHH JEQ-H11 (see Table 
S1). Two rounds of panning, one at low stringency and a second at higher stringency were 
performed as described by Vrentas et al. (2016). Typically, at least ninety-five random 
clones from selected populations obtained using each panning method were screened for 
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expression of VHHs that bound to ciBoNT/B1. A total of 55 VHHs that appeared to be 
unique based on DNA fingerprinting were selected for DNA sequencing to identify VHHs 
that derive from common B cell precursors based on homology within the CDRs. From this 
information, 21 unique VHHs were selected for expression and characterization. Following 
characterization, 15 clonally independent groups were identified. The Figure S1A shows the 
sequences of 17 unique selected VHH, including two pair of apparently related VHHs (JLK-
G12 and JLO-G11; JLI-G10 and JFM-A11), which derive from different libraries (Table 
S1). The monomeric VHH coding DNAs were initially expressed and purified as His6-
tagged recombinant Escherichia coli thioredoxin (Trx) fusions with a carboxy-terminal E-
tag, as previously described (Mukherjee et al., 2014).
LCHN/A (M1–K871) was amplified from catalytically inactive BoNT/A that carries three 
mutations (E224Q/R363A/Y366F) (Gu et al., 2012) and cloned into pCDF-duet vector 
following an N-terminal His6 tag and a PreScission cleavage site. Rat Syt II (M1–I61) (Jin et 
al., 2006), Syt II (M1–C90), LC/A (P2–K438), HCB (E859–E1291) (Jin et al., 2006), ciA-
B5, three anti-BoNT/B1 VHHs (JLK-G12, JLI-H11, and JLI-G10), and D12/11/B5 were 
cloned into pGEX-6P-1 for expression following the N-terminal GST and a PreScission 
cleavage site. Two anti-BoNT/A1 VHHs (ciA-D12 and ciA-H7) were cloned into 
pGEX-4T-2 vector following the N-terminal GST and a thrombin cleavage site. To facilitate 
co-expression of HCB and VHHs, three anti-BoNT/B1 VHHs (JLK-G12, JLI-H11, and JLO-
G11) were additionally cloned into pAC28 vector following the N-terminal His6 tag (Kholod 
and Mustelin, 2001). HNA, HNA S622C/V653C (HNADS), ALc-B8 and ciA-F12 were 
expressed and purified as described previously (Gu et al., 2012; Lam et al., 2018; Tremblay 
et al., 2010).
His6-LCHN/Ai was expressed in the E. coli strain BL21-RIL (DE3) (Agilent). Transformed 
bacteria were grown at 37°C in TB medium in the presence of spectinomycin and 
chloramphenicol. Expression was induced with 0.1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG) when OD600 reached ~1.0. Temperature was then decreased to 
25°C and expression was continued for 16 hr. Syt II (1–61), Syt II (1–90), LC/A, HCB, ciA-
B5, ciA-D12, ciA-H7, and D12/11/B5 were expressed in E. coli strain BL21-Star (DE3) 
(Invitrogen). GST-tagged JLK-G12, JLI-H11, and JLI-G10 were expressed in the E. coli 
strain Origami B (DE3) (Novagen). GST-tagged HCB was co-expressed with His-tagged 
JLK-G12, JLI-H11, or JLO-G11 in E. coli strain BL21-Star (DE3). Bacteria were cultured at 
37°C in LB medium containing ampicillin and/or kanamycin. Temperature was reduced to 
18°C when OD600 reached ~0.6. Expression was induced with 1 mM IPTG and continued at 
18°C for 16 hr. Cells were harvested by centrifugation and stored at −20°C until use.
For protein purification, bacteria were re-suspended in a buffer containing 50 mM Tris (pH 
8.0), 400 mM NaCl, and 0.4 mM PMSF and lysed by sonication. His6–LCHN/A was 
purified using a Ni-NTA (nitrilotriacetic acid, QIAGEN) affinity column in the same buffer 
supplemented with 20 mM imidazole and subsequently eluted with 250 mM imidazole. The 
eluted proteins were pooled followed by His-tag removal using PreScission protease and 
dialysis at 4°C against a buffer composed of 20 mM sodium acetate (pH 4.3) and 100 mM 
NaCl. This protein was further purified by MonoS ion-exchange chromatography (GE 
Healthcare) in a buffer containing 20 mM sodium acetate (pH 4.3) and eluted with a NaCl 
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gradient, followed by Superdex-200 size exclusion chromatography (SEC; GE Healthcare) 
in 150 mM NaCl and 10 mM HEPES (pH 7.5).
All GST-tagged proteins were purified using Glutathione Sepharose 4B resins (GE 
Healthcare) in 50 mM Tris (pH 8.0), 400 mM NaCl, and eluted from the resins after on-
column cleavage using either PreScission protease (HCB, LC/A, ciA-B5, D12/11/B5, JLK-
G12, JLI-H11, and JLI-G10) or thrombin (ciA-H7 and ciA-D12). Uncleaved GST-tagged 
proteins (Syt II (1–61), Syt II (1–90), and GST-F12) were eluted in the same buffer 
supplemented with 20 mM reduced glutathione. The proteins were further purified by 
Superdex-200 Increase or Superdex-75 SEC in 10 mM HEPES (pH 7.4) and 150 mM NaCl. 
The complexes of HCB with JLK-G12, JLI-H11, or JLO-G11 were purified by Ni-NTA 
column, separately, followed by GST affinity column, on-column GST cleavage using 
PreScission protease, and Superdex-200 Increase SEC (150 mM NaCl, 10 mM HEPES, pH 
7.4). The HCB–JLI-G10 complex was made by mixing the purified HCB and JLI-G10 at a 
molar ratio of 1:1.5 for 1 hr on ice, followed by purification using Superdex-200 Increase 
SEC (10mM HEPES, pH 7.4, and 150 mM NaCl). The LCHN/A–B5–D12–H7 complex or 
the LCHN/A–D12/11/B5–H7 complex was assembled by mixing the purified LCHN/A with 
the purified VHHs or VNA at a molar ratio of 1:1.5 for 1 hr on ice. The complexes were 
further purified by Superdex-200 Increase SEC (150 mM NaCl and 10 mM HEPES, pH 
7.4). Each protein was concentrated to ~5 mg/ml using Amicon Ultra centrifugal filters 
(Millipore) and stored at −80°C until further characterization or crystallization.
All VHH heterodimer VNAs coding DNAs were synthesized (Genscript) and expressed 
either as cytosolic Trx fusion proteins in E. coli, or as secreted proteins in mammalian cells. 
Bacterial expression, purification, and quantification were performed as previously 
described (Mukherjee et al., 2014). VNAs used in the mouse studies reported in this work 
were expressed by mammalian cells and purified from conditioned media by standard nickel 
affinity methods (Genscript). The purified proteins were analyzed by SDS-PAGE and 
western blot and shown to have over 95% purity. Quantification was by Bradford assay with 
BSA standards.
Pull down assay—To examine the interaction between HCB and rat Syt II (1–61), 20 μg 
of GST–Syt II (1–61) was immobilized on GST resins as the bait in a buffer containing PBS 
and 0.01% Tween 20. HCB (300 nM) or HCB pre-incubated with 600 nM of JLI-G10, JLK-
G12, or JLI-H11 was pull-down as the preys at 8°C for 1 hr. After washing with the same 
buffer for three times, samples were boiled with SDS loading dye and analyzed by SDS-
PAGE. The pull-down assay between HCB and Syt II (1–90) was performed using the same 
protocol, except that the buffer contained PBS and 0.5% Triton X-100 in the presence or 
absence of ~60 μM of GT1b. The pull-down samples were boiled with SDS loading dye 
supplemented with 4 M Urea.
Liposome co-sedimentation assay—Large unilamellar vesicles (LUV) were prepared 
as previously described (Lam et al., 2018). Briefly, lipids (1,2-dioleoyl-sn-glycero-3-
phospho-L-serine (DOPS) and 1-palmitoyl-2-(9,10-dibromostearoyl)phosphatidylcholine 
(BrPC)) (Avanti Polar Lipid) were dissolved in chloroform while GT1b trisodium salt (Santa 
Cruz Biotechnology) was dissolved in methanol. The lipids at the indicated molar ratios 
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were mixed and then dried under nitrogen gas and placed under vacuum for overnight. The 
dried lipids were rehydrated and subjected to 5–10 rounds of freezing and thawing cycles. 
Liposomes were prepared by extrusion through a 200 nm pore membrane using an Avanti 
Mini Extruder according to the manufacturer’s instructions.
The HCB–GT1b binding experiment was conducted by mixing 1 μM of HCB or HCB pre-
incubated with 2 μM of VHH (JLI-G10, JLK-G12, or JLI-H11) with ~80 μg of liposomes 
composed of 70/20/10 mol% of BrPC/DOPS/GT1b. The protein–liposome mixture was then 
incubated in a buffer containing 50 mM NaCl, 20 mM MES (pH 6.5) at room temperature 
for 30 min followed by spinning progressively at 4,000 × , 9,000 × , and 16,000 × g for 30 
min each. Supernatant and pellet were separated and analyzed by SDS-PAGE.
To study the effect of ciA-B5 on HNA–lipid interaction, HNA (25–200 nM) or HNA pre-
bound with ciA-B5 at 1:1.5 molar ratio, was incubated with ~45 μg of liposomes composed 
of 80/20 mol% of BrPC/DOPS in a buffer containing 100 mM NaCl and 50 mM sodium 
acetate (pH 4.6) at room temperature for 1 hr. In some experiments, the HNA-bound 
liposomes were further mixed with ciA-B5 for 1 hr and centrifuged.
To further characterize the ciA-B5–HNA-liposome association, the centrifuged pellet of 
liposomes incubated with 100 nM of HNA or HNA–ciA-B5 complex was re-suspended in a 
buffer containing either PBS, or 1 M NaCl and 50 mM sodium acetate (pH4.6), or 0.15 M 
NaCl and 50 mM CAPS (pH 11), or 2% Triton X-100 (Sun et al., 2011), before another 
round of centrifugation.
Calcein dye release assay—Dried lipid containing 90/10 mol% of asolectin/cholesterol 
was resuspended in 150 mM NaCl, 20 mM HEPES (pH 7.0), 1 mM EDTA, and 50 mM 
calcein. Free calcein dye was separated from calcein-entrapped liposomes by desalting 
(Zeba). Fluorescence was measured on a Spectramax M2e cuvette module with excitation at 
493 nm and emission at 525 nm. In the assay, liposomes were diluted in 150 mM NaCl, 20 
mM sodium acetate (pH 4.6), 1 mM EDTA to give a final concentration of 0.1 mM and 
incubated until the fluorescence signal was stable. HNA or HNA pre-incubated with ciA-B5 
at a 1:1.5 molar ratio was added at 25–400 nM and the fluorescence intensity was recorded 
for 10 minutes. The reaction was stopped by adding 0.1% Trion X-100. The percentage of 
fluorescence change was calculated as (F – Finitial)/(Ffinal – Finitial). The initial rate of calcein 
dye release was deduced from the slope of the linear part of the curve. The experiments were 
repeated three times independently.
Membrane depolarization assay—Liposomes composed of 70/20/10 mol% of DOPC/
DOPS/cholesterol were prepared in 200 mM NaCl, 1 mM KCl, and 10 mM HEPES (pH 
7.0). To create a trans-positive membrane potential (+ 135 mV), liposomes were diluted in 
200 mM KCl, 1 mM NaCl, and 10 mM sodium acetate (pH 4.6). Membrane potential was 
monitored using 6 μM ANS. Valinomycin was added at time 0 s to give a final concentration 
of 30 nM. At 180 s, 40 nM of HNA pre-incubated with 0–200 nM of ciA-B5 or HNA S622C/
V653C (HNADS) was added and the fluorescence intensity at 490 nm was monitored for 6 
minutes with excitation at 380 nm. The reaction was stopped by adding 2 μM of gramicidin 
from Bacillus anerinolyticus (Sigma-Aldrich). The fluorescence change relative to the 
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maximal change in the presence of gramicidin was calculated as (F – Finitial)/(Ffinal – Finitial). 
The experiments were repeated three times independently.
8-anilinonaphthalene-1-sulfonic acid binding assay—LC/A, LC/A-VHH, or VHH 
was incubated at ~1 μM with 100 μM ANS for 15 min in either 50 mM sodium acetate (pH 
4.0–5.6) or 50 mM Bis-Tris (pH 6–7). All buffers contained 100 mM NaCl. Fluorescence 
intensity were recorded at 25 °C using a Molecular Devices SpectraMax M2e 
spectrophotometer with excitation at 370 nm and emission at 478 nm. The fluorescence 
intensity was corrected by subtraction of background fluorescence from ANS in a buffer 
without protein. Error bars indicate SD of three replicate measurements.
The binding of ANS to HNA was carried out as previously described (Lam et al., 2018). 
Briefly, HNA, HNA–ciA-B5, or ciA-B5 was incubated at ~1.34 μM with 100 μM of ANS for 
15 min in a buffer containing 100 mM NaCl and either 50 mM sodium acetate (pH 4–5.2) or 
50 mM Bis-Tris (pH 6–7). The peak emission intensity at 466 nm was recorded.
Thermal denaturation assay—The thermal stability of LC/A or LC/A–VHH was 
measured using a fluorescence-based thermal shift assay on a StepOne real-time PCR 
machine (Life Technologies). LC/A with or without VHH were incubated for 30 min in a 
buffer containing 0.1 M NaCl and either 50 mM sodium acetate (pH 4–5.5) or 50 mM Bis-
Tris (pH 6–6.5). Immediately before the experiment, the protein (1 μM) was mixed with the 
fluorescent dye SYPRO Orange (Sigma-Aldrich). The samples were heated from 20 °C to 
90 °C in a standard ramp rate of 1.5°C/min. The midpoint of the protein-melting curve (Tm) 
was determined using the analysis software provided by the instrument manufacturer. The 
experiment was performed in triplicate.
Crystallization—Initial crystallization screens were performed using a Gryphon 
crystallization robot (Art Robbins Instruments) and high-throughput crystallization screen 
kits (Hampton Research and QIAGEN). Extensive manual optimizations were performed at 
18°C when proteins were mixed with reservoir solution at 1:1 ratio.
1. The best single crystals of HCB–JLI-G10 were grown by the hanging-drop vapor 
diffusion method at a protein concentration of 5 mg/ml with a reservoir solution 
containing 15% PEG 20,000 and 0.1 M MES (pH 6.5).
2. Crystals of HCB–JLK-G12 were obtained by the hanging-drop vapor diffusion 
method at a protein concentration of 4 mg/ml with a reservoir solution containing 
0.2 M ammonium sulfate, 14% PEG 8,000, and 0.1 M MES (pH 6.0).
3. Crystals of HCB–JLO-G11 were obtained by the sitting-drop vapor diffusion 
method at a protein concentration of 5 mg/ml with a reservoir solution containing 
20% Ethanol and 0.1 M Tris (pH 8.5).
4. Crystals of HCB–JLI-H11 were obtained by the sitting-drop vapor diffusion 
method at a protein concentration of 5 mg/ml with a reservoir solution containing 
0.1 M KCl, 15% PEG 5,000 MME, and 0.1 M MES (pH 6.5).
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5. Crystals of LCHN/Ai–B5–D12–H7 were grown by the hanging-drop vapor 
diffusion method at a protein concentration of 5 mg/ml with a reservoir solution 
containing 11% PEG 20,000 and 0.1 M sodium cacodylate (pH 6.4). Micro-
seeding was necessary to obtain single crystals. Despite extensive efforts, 
crystallization of other LCHN/Ai–VHHs complexes, such as LCHN/Ai–B5–F12 
and LCHN/Ai–B5–F12-H7, and the HNA–ciA-B5 complex was not successful.
6. Crystals of LCHN/Ai–D12/11/B5–H7 were obtained by the hanging-drop vapor 
diffusion method at a protein concentration of 3 mg/ml with a reservoir solution 
containing 13% PEG 20,000 and 0.1 M sodium cacodylate (pH 6.6).
Data collection and structure determination—All crystals were cryoprotected in 
their original mother liquor supplemented with 20%–25% (v/v) ethylene glycol. The X-ray 
diffraction data for the crystals of HCB–JLK-G12 and LCHN/Ai–B5–D12–H7 were 
collected at 100 K at beamline BL9-2 at the Stanford Synchrotron Radiation Lightsource 
(SSRL). All other data were collected at 100 K at the NE-CAT beamline 24-ID-E, Advanced 
Photon Source (APS). The data were processed with iMOSFLM (Battye et al., 2011) or 
XDS as implemented in RAPD (https://github.com/RAPD/RAPD) (Kabsch, 2010). Data 
collection statistics are summarized in Table S2. Structures of the HCB–JLI-G10, HCB–JLO-
G11, HCB–JLK-G12, and HCB–JLI-H11 complexes were determined by molecular 
replacement using the Phaser software (McCoy et al., 2007) with HCB (PDB: 2NM1) (Jin et 
al., 2006) and the homology models of JLI-G10, JLO-G11, JLK-G12, or JLI-H11 that were 
built based on a VHH in PDB 5L21 (Yao et al., 2017) as the search models. Structures of the 
LCHN/Ai–B5–D12–H7 and LCHN/A–D12/11/B5–H7 complexes were solved by molecular 
replacement with Phaser using LCHN/A (PDB: 3V0A) (Gu et al., 2012) and the homology 
models of ciA-B5, ciA-D12, and ciA-H7 as the search models. Manual model building and 
refinement were performed in COOT (Emsley et al., 2010), PHENIX (Adams et al., 2010), 
and CCP4 suite (Winn et al., 2011) in an iterative manner. The refinement progress was 
monitored with the free R value using a 5% randomly selected test set (Brünger, 1992). The 
structures were validated through MolProbity (Chen et al., 2010) and showed excellent 
stereochemistry. Structural refinement statistics are listed in Table S2. All structure figures 
were prepared with PyMol (https://pymol.org/2/).
Gel filtration analysis—Toxin fragment (LCHN/A or HCB) was incubated with various 
VHHs or VNAs at a toxin:VHH/VNA = 1:1 or 1:5 molar ratio in PBS at 4°C for 1 hr. The 
protein mixtures were then separated by Superdex-200 SEC in PBS.
SNAP-25 endopeptidase assay—LC/A (2–438) at 1 nM was pre-incubated with 10–
100 nM VHH for 15 min and subsequently added to 5 μM of SNAP-25(80–206)-His6 in a 
buffer containing 20 mM HEPES (pH 7.4), 5 μM MgSO4, 5 μM ZnSO4, and 0.1% Tween20. 
After incubation at room temperature for 30 min, the reactions were stopped by mixing with 
SDS-loading dye and boiling for 5 min. The samples were subjected to SDS-PAGE analysis.
Characterization of BoNT/B VHH binding and neutralization properties—VHHs 
(E-tagged) were tested for binding to the various recombinant BoNT preparations 
(ciBoNT/B1, HCB, LC/B, etc) by standard ELISAs (Mukherjee et al., 2012) using plates 
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coated with 100 μl of 1 μg/ml of the protein, or by first coating plates with 5 μg/ml of a 
BoNT-binding VHH (myc tagged) followed by a blocking step and then capturing a 1 ug/ml 
BoNT preparation. Typically ELISAs started at 125 nM VHH and 1:5 dilutions were 
performed prior to detection with HRP-goat anti-E-tag (Bethyl). BoNT/B neutralization 
studies were done similar to those previously reported for VHHs binding to BoNT/A 
(Mukherjee et al., 2012), but employing 1 nM BoNT/B treatments of primary neurons and 
detecting VAMP cleavage on western blots as a ratio of VAMP to SNAP25 (1:25,000 rabbit 
anti-SNAP25 combined with 1:1000 rabbit anti-VAMP (Millipore)) and detected with 
1:10,000 HRP-goat anti-rabbit IgG (GE Healthcare). BoNT cleaved VAMP is not recognized 
by the anti-VAMP antibody, so the assay relies on the ratio of intact VAMP:SNAP25 as 
comparted to controls.
Mouse toxin lethality assay—Mouse lethality assays were performed similarly as 
previously described (Mukherjee et al., 2012). Briefly, female CD1 mice 22–27 g each 
(Charles River Labs) were grouped to minimize inter-group weight variation. VHH and 
VNA proteins were diluted in PBS at 40 pmol per mouse. BoNT holotoxins were prepared 
separately in PBS + 0.2% gelatin (Sigma-Aldrich). For co-intoxication assay, VNA and 
BoNT were combined in a total volume of 250 μl and incubated at room temperature for 30 
min prior to administration by intraperitoneal injection. For separated administration 
experiments, VNA was injected to mice via tail vein at 5, 30, or 60 minutes prior to 
administration of toxins by intraperitoneal injection. Mice were observed at least twice per 
day and scored for survival and clinical signs using the following rubric: mild abdominal 
paradox (score of 1); severe abdominal paradox (2); agonal respiratory pattern (3); lethargy 
(1); generalized body weakness (2); total body paralysis (lack of righting reflex, 3); and 
death (16). Progression of toxic signs and time to death were determined for each mouse and 
averaged within each treatment group.
QUANTIFICATION AND STATISTICAL ANALYSIS
All in vitro assays were performed in triplicate. For pulldown and liposome co-
sedimentation assays (Figures 2, 3, and S7), protein band intensities was quantified by 
software ImageJ and the data were reported as mean ± S.D..
DATA AND CODE AVAILABILITY
Atomic coordinates and structure factors for HCB–JLI-G10, HCB–JLO-G11, HCB–JLK-
G12, HCB–JLI-H11, LCHN/Ai–D12–B5–H7, and LCHN/Ai–D12/11/B5–H7 have been 
deposited in the Protein Data Bank under accession codes 6UHT, 6UL4, 6UFT, 6UC6, 6UI1, 
6UL6, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Crystal structures of six VHHs that bind and neutralize BoNT/A1 or 
BoNT/B1
• Three VHHs inhibit the membrane insertion or the light chain unfolding of 
BoNT/A1
• Three VHHs block the synaptotagmin, ganglioside, and/or lipid binding of 
BoNT/B1
• Rationally designed bifunctional VHH heterodimers show superior antitoxin 
potency
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Figure 1. Structures of HCB in Complex with JLI-G10, JLK-G12, or JLI-H11
(A) A model illustrating the binding of HCB to ternary receptors: Syt II, disialoganglioside 
1a (GD1a), and lipid membrane.
(B) A model of HCB simultaneously bound with three VHHs. HCB is positioned in the same 
orientation as in (A).
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Figure 2. VHHs JLI-G10, JLK-G12, and JLI-H11 Inhibit HCB Binding to Host Receptors
(A) JLI-G10 occupies the ganglioside-binding pocket on HCB. HCB–JLI-G10 is 
superimposed with HCB–GD1a (PDB: 4KBB). GD1a is drawn in the line model. The JLI-
G10-binding interface is colored cyan, whereas regions overlapping or non-overlapping with 
the GD1a-binding site are colored pink and magenta, respectively. Key residues on the 
CDR3 loop (orange illustration) that interact with the conserved ganglioside recognition 
motif are shown in sticks.
(B) JLI-G10 and JLK-G12 inhibit the binding of HCB to GT1b-containing liposomes. HCB 
pre-bound with VHHs was incubated with liposomes containing 70/20/10 mol% BrPC/
DOPS/GT1b. After liposomes were pelleted, HCB and VHHs in the input (I), supernatant 
(S), and pellet (P) fractions were analyzed by SDS-PAGE.
(C) JLI-G10 (orange) occupies the HC-loop (cyan illustration) of BoNT/B1. Hydrophobic 
residues reported to be crucial for lipid interaction are indicated. The structure of the apo 
BoNT/B1 (PDB: 2NP0) is shown (white illustration) for comparison.
(D) JLK-G12 and JLI-H11, but not JLI-G10, prevent HCB from binding to Syt II (1–61). 
Pull-down assay was performed using HCB as a prey and the GST-tagged Syt II (1–61) as a 
bait. After binding, the GST resins were washed three times and the bound proteins were 
released and subjected to SDS-PAGE.
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(E) JLI-G10 and JLK-G12 block the interaction of HCB to its ternary receptors. GST-tagged 
Syt II (1–90) was used as baits. Pull-down assay was done in a buffer containing 0.5% 
Triton X-100, with the addition of GT1b as indicated. These experiments were performed in 
triplicate. Uncropped images of gels and quantification of protein band intensities are shown 
in Figures S7A-S7F.
(F) JLK-G12 binds at the Syt-binding site on HCB. The JLK-G12- and the Syt II-binding 
surfaces of HCB are colored cyan and magenta, respectively. The overlapping interface is 
colored pink. Note that residue F101 in the CDR3 loop of JLK-G12 (illustration) and F54 of 
Syt II (line) occupy the same hydrophobic pocket on HCB.
(G) Superposition of HCB–JLI-H11 (cyan and purple) and HCB–Syt II complexes (white; 
PDB: 2NM1). Note that JLI-H11 creates a side-to-side clash (arrow) with the N terminus of 
Syt II (white illustration). See also Figures S2, S3, and S6.
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Figure 3. VHH ciA-B5 Inhibits the Channel Formation of HNA
(A) ciA-B5 occupies the membrane-interacting region on HNA. The putative transmembrane 
region is colored brown, and the BoNT-switch is highlighted in pink. The CDR1, 2, and 3 of 
ciA-B5 are colored in red, orange, and blue, respectively.
(B) Calcein dye release assay. HNA(0–400 nM) was tested with liposomes loaded with 50 
mM calcein at pH 4.6, in the presence or absence of ciA-B5. The rate of calcein dye release 
was determined based on the increase of fluorescence at 525 nm during excitation at 493 
nm.
(C) Membrane depolarization assay. Liposomes were polarized at a positive internal voltage 
by adding valinomycin in the presence of a transmembrane KCl gradient. Membrane 
potential was measured using the voltage-sensitive fluorescence dye ANS. After 3 min, HNA 
with various concentrations of ciA-B5 was added. The data are presented as ± SD; n = 3.
(D) Liposome co-sedimentation assay. HNA(25–200 nM) or HNA pre-bound with ciA-B5 in 
1:1.5 molar ratio was incubated with liposomes containing 80/20 mol% BrPC/DOPS. 
Alternatively, HNA was incubated with liposomes followed by co-incubation with ciA-B5 
before centrifugation. After liposomes were pelleted, HNA and ciA-B5 in the input (I), 
supernatant (S), and pellet (P) fractions were analyzed by SDS-PAGE.
(E) The pellet fraction of liposomes incubated with 100 nM of HNA or HNA–ciA-B5 was re-
suspended in buffers containing either PBS, 1 M NaCl and 50 mM sodium acetate (pH4.6), 
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0.15 M NaCl and 50 mM CAPS (pH 11), or 2% Triton X-100. The re-suspended liposomes 
were re-centrifuged and the supernatant (S2) and pellet (P2) fractions were separated. These 
experiments were performed in triplicate and quantification of protein band intensities are 
shown in Figures S7L-S7N. Uncropped images of gels are shown in Figures S7G-S7K.
See also Figures S2, S4, and S6.
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Figure 4. VHH ciA-H7 Interferes with Low-pH-Triggered LC/A Unfolding
(A) Structure of ciA-D12- and ciA-H7-bound LCHN/A. Only the BoNT LC domain is 
shown for clarity. The ciA-H7-, ciA-D12-, and ciA-F12-binding epitopes on LC/A are 
colored pink, orange, and blue, respectively. The corresponding secondary structures are 
labeled. VHHs ciA-H7 and ciA-D12 are drawn as cyan and green ribbons, respectively.
(B) Thermal stability of LC/A, LC/A–ciA-D12, LC/A–ciA-H7, and LC/A–ciA-F12. The 
thermal stability of the proteins was measured using a fluorescence-based thermal shift 
assay on a StepOne real-time PCR system (ThermoFisher). Protein melting was monitored 
using a hydrophobic dye, SYPRP Orange (Sigma-Aldrich), as the temperature was increased 
in a linear ramp from 20°C to 90°C. The midpoint of the protein-melting curve (Tm) was 
determined using software provided by the instrument manufacturer. The data are presented 
as mean ± SD; n = 3.
(C) ANS fluorescence assay. LC/A (residues 2–438) at 0.5 mg/ml (0.98 mM) was incubated 
with equimolar ratio of VHH in a buffer containing either 50 mM sodium acetate (pH 4.0–
6.0), sodium citrate (pH 6.0), or HEPES (pH 7.0). All buffers contain 100 mM NaCl and 100 
mM ANS. The mean values of fluorescence intensity at 478 nm are shown. Error bar 
represents SD of three replicate experiments.
See also Figures S2, S4, and S6.
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Figure 5. Rational Design of VNAs to Allow Simultaneous Binding of the Parental VHHs to a 
Single Toxin Molecule
(A and B) Inter-molecular distances between selected VHHs that target BoNT/A1 (A) and 
BoNT/B1 (B), respectively. The Cα atoms of the N- and C-terminal residues are shown in 
blue and red spheres, respectively.
(C–E) Gel filtration analysis to distinguish simultaneous versus non-simultaneous binding 
VNAs. D12/11/B5 and D12/11/H7 (C) were examined using LCHN/A. G10/12/G12 and 
G12/5/G10 (D) and H11/20/G12 and H11/3/G12 (E) were examined using HCB. Elution 
profiles were shown for the toxin fragments in complex with the parental VHHs (top panel), 
designer VNAs with optimal spacers to allow simultaneous binding (middle panel), or 
control VNAs with spacers too short to allow simultaneous binding (bottom panel). The 
toxin fragments were incubated with parental VHHs at 1:1 molar ratio. The bivalent VNAs 
were tested at 1:1 (blue curve) or 1:5 (green curve) molar ratio. The elution profiles of the 
free VNAs are colored gray. The peak elution volumes of the monomeric VNA-toxin 
complex and the VNA alone are indicated by red and blue arrows, respectively.
See also Figure S4.
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Figure 6. BoNT/A1 Intoxication in Mice Is Prevented by Co-administration of the Designer 
VNAs
Symptoms of BoNT/A1 intoxication and lethality were monitored following administration 
of bivalent VNAs (D12/11/B5, D12/11/H7, or H7/30/B5) or toxin only. Time to death is 
plotted as % survival following co-injection of the indicated dose of BoNT/A1 and VNAs in 
groups of five mice. See also Figure S5.
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Figure 7. BoNT/B1 Intoxication in Mice Is Prevented by Co-administration of the Designer 
VNAs
Symptoms of BoNT/B1 intoxication and lethality were monitored following administration 
of bivalent VNAs G10/12/G12, G12/5/G10(A), H11/20/G12, H11/3/G12 (B), or toxin only. 
Time to death is plotted as % survival following co-injection of the indicated dose of 
BoNT/B and VNAs in groups of five mice. See also Figure S5.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
HRP-goat anti-E-tag Bethyl Cat#:A190-132P; RRID: 
AB_345220
Rabbit polyclonal anti-SNAP25 EMD Millipore Cat#: AB5871; RRID: AB_2192200
Rabbit polyclonal anti-VAMP Millipore Cat#: AB5856; RRID: AB_92090
HRP-goat-anti-rabbit IgG GE Healthcare Cat#: NA935; RRID: AB_772207
Bacterial and Virus Strains
E. coli BL21 Star (DE3) Invitrogen Cat#: C6010-03
E. coli BL21-CodonPlus(DE3)-RIL Agilent Technologies Cat#: 230245
E. coli Origami B Novagen Cat#: 70837-3
Biological Samples
Chemicals, Peptides, and Recombinant Proteins
Precision Protease This Paper N/A
Human alpha-thrombin Haematologic Technologies Cat#: HCT-0020
Inactive BoNT/B1 This Paper N/A
VNA D12/11/B5 (Mukherjee et al., 2012) Genscript N/A
VNA D12/11/H7 (Mukherjee et al., 2012) Genscript N/A
VNA H7/30/B5 (Mukherjee et al., 2012) Genscript N/A
VNA G10/12/G12 (Figure S1) Genscript N/A
VNA G12/5/G10 (Figure S1) Genscript N/A
VNA H11/20/G12 (Figure S1) Genscript N/A
VNA H11/3/G12 (Figure S1) Genscript N/A
BoNT/A1 Metabiologics Inc. Cat#: BoNT/A complex
BoNT/B1 Metabiologics Inc. Cat#: BoNT/B complex
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) Avanti Polar Lipid Cat#: 850375C
1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) Avanti Polar Lipid Cat#: 840035C
1-palmitoyl-2-(9,10-dibromo)stearoyl phosphatidylcholine (BrPC) Avanti Polar Lipid Cat#: 850481C
GT1b trisodium salt Santa Cruz Biotechnology Cat#: sc-221661
Asolectin Sigma-Aldrich Cat#: 11145
Cholesterol Avanti Polar Lipid Cat#: 700000
Gramicidin Sigma Aldrich Cat#: G5002
SYPRO Orange Sigma Aldrich Cat#: S5692
Critical Commercial Assays
Rneasy Kit QIAGEN Cat#: 74104
Crystal Screen HT Hampton Research Cat#: HR2-130
SaltRx HT Hampton Research Cat#: HR2-136
Index HT Hampton Research Cat#: HR2-134
ProComplex Suite QIAGEN Cat#: 130915
Deposited Data
HCB–JLI-G10 structure PDB 6UHT
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REAGENT or RESOURCE SOURCE IDENTIFIER
HCB–JLK-G12 structure PDB 6UFT
HCB–JLO-G11 structure PDB 6UL4
HCB–JLI-H11 structure PDB 6UC6
LCHN/Ai–B5–D12–H7 structure PDB 6UI1
LCHN/Ai–D12/11/B5–H7 structure PDB 6UL6
Experimental Models: Cell Lines
Rat primary cerebellar neuron cultures 5-7d Spraque-Dawley rats (Eubanks et al., 2010)
Experimental Models: Organisms/Strains
Female CD1 Mouse Charles River Labs Cat#: CD1(ICR)
Alpacas Local farms N/A
Oligonucleotides
LcHN(1–871)_F: attactttcatatcttaaattcaatatagaagtattaataa 
tttacttaatatattcagtaaatgtagataataatctcagtaaatg
This Paper N/A
LcHN(1–871)_R: catttactgagattattatctacatttactgaatatattaa 
gtaaattattaatacttctatattgaatttaagatatgaaagtaat
This Paper N/A
SytII(1–90)_F: GGCCGGATCCATGAGAAACATCTTCAAG 
AGGAACCAG
This Paper N/A
SytII(1–90)_R: GGCCGTCGACTTAGCACTTCTTACAGAT 
GCAGAAGC
This Paper N/A
LC/A(2–438)_F: ctacttattgtatcctttatctaatgatttctatttagaagtt 
attatccctcttacacatagcaact
This Paper N/A
LC/A(2–438)_R: agttgctatgtgtaagagggataataacttctaaatag 
aaatcattagataaaggatacaataagtag
This Paper N/A
Recombinant DNA
pCDF-duet-1 Novagen Cat#: 71340
pGEX-6p-1 GE Healthcare Cat#: 28954648
pGEX-4t-2 GE Healthcare Cat#: 28954550
Software and Algorithms
iMOSFLM (Battye et al., 2011) https://www.mrc-lmb.cam.ac.uk/
mosflm/imosflm/ver730/
introduction.html
XDS (Kabsch, 2010) https://github.com/RAPD/RAPD
Phaser (McCoy et al., 2007) https://www.phenix-online.org/
Coot (Emsley et al., 2010) https://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
Phenix (Adams et al., 2010) http://www.phenix-online.org
CCP4 (Winn et al., 2011) http://www.ccp4.ac.uk/
Pymol The PyMOL Molecular 
Graphics System, Version 
1.7.Schrödinger, LLC.
https://pymol.org/2/
Clustal Omega (Sievers et al., 2011) https://www.ebi.ac.uk/Tools/msa/
clustalo/
ESPript 3.0 (Robert and Gouet, 2014) http://espript.ibcp.fr/ESPript/
ESPript/
PDBe-PISA (Krissinel and Henrick, 2007) https://www.ebi.ac.uk/pdbe/pisa/
Graphpad v7.2 Prism https://www.graphpad.com/
scientific-software/prism/
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